	Cardiovascular complications of antineoplastic treatment in prostate cancer patients and compensatory strategies for clinical management. Eur J Intern Med Tsiamis N, Toulgaridis F, Stefanou E, Tountas C, Tsitsinakis G, Ballas E, Maurogenis I, Kitsiou A, Kole C. PMID: 42386405 [PubMed - as supplied by publisher]
	Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052. Eur Urol Lorenzo GD, Maio MD. PMID: 42386399 [PubMed - as supplied by publisher]
	Incidental Renal Cell Carcinoma in an Active-Duty Fighter Pilot. Aerosp Med Hum Perform Woodside S, Nguyen D, Smith J, Udy A, Whetstone T, Zhang J. PMID: 42386197 [PubMed - indexed for MEDLINE]
	Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review. Clin Genitourin Cancer Rodríguez-Parras P, Ángel Arrabal-Polo M, Arrabal-Martín M. PMID: 42385473 [PubMed - as supplied by publisher]
	Impact of 18-FDG PET-CT on the preoperative staging and management of Incidental Gall Bladder Cancer (IGBC)- A prospective study from a tertiary care centre in North India. Eur J Surg Oncol Kohli M, Goel S, Iqbal A, Aggarwal A, Gupta M, Garg P, Goel V, Talwar V, Singh S. PMID: 42385409 [PubMed - as supplied by publisher]
	Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma. J Immunother Cancer McKay RR, Serzan M, Xie W, McGregor BA, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan BL, Rose T, Stadler WM, Mcdermott DF, Choueiri TK. PMID: 42386345 [PubMed - indexed for MEDLINE]
	Empty Versus Full Bladder Protocols in Radiotherapy Planning for Localised Prostate Cancer: A Dosimetric Study. J Med Imaging Radiat Oncol Nield RL, Ramani S, Christie DRH, Trono IL. PMID: 42385367 [PubMed - as supplied by publisher]
	Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer. Cancer Med Odagiri K, Tasaki Y, Naiki T, Morikawa T, Iida K, Noda Y, Banno R, Isobe T, Shimizu N, Aoki M, Mimura Y, Sugiyama Y, Nagai T, Etani T, Hamamoto S, Ando R, Kawai N, Furukawa-Hibi Y, Yasui T. PMID: 42385219 [PubMed - indexed for MEDLINE]
	Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. Int J Urol Matsumoto S, Tanaka H, Matsushita Y, Kojima T, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Yamashita S, Taniguchi H, Goto S, Fukuda H, Kawasaki Y, Kitamura H, Miyake H, Fujii Y, Japanese Urological Oncology Group. PMID: 42385189 [PubMed - indexed for MEDLINE]
	Outcomes of Gemcitabine, Oxaliplatin, and Paclitaxel Salvage Chemotherapy in Japanese Patients With Relapsed or Refractory Germ Cell Tumors. Int J Urol Aigase T, Kouno T, Kubo H, Matsumoto T, Suzuki A, Nakaigawa N, Kishida T. PMID: 42385183 [PubMed - indexed for MEDLINE]
	Prognostic Factors for Relapse and Mortality Risk in Chilean Patients With Testicular Cancer: A Retrospective Cohort Study. JCO Glob Oncol Ríos-Correa V, Bennett-Laso J, Guerra-Pérez D, Jiménez-Galindo M, Avendaño-Arriagada F, Correa-Duque M, Villarroel A, Miranda C, Ibañez C, Majerson A, Briones-Carvajal J. PMID: 42385096 [PubMed - indexed for MEDLINE]
	Evaluation and comparison of voided urine and bladder washing cytologies according to the Paris system. Rev Assoc Med Bras (1992) Bulut A, K. PMID: 42385039 [PubMed - indexed for MEDLINE]
	Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med Choueiri TK, Motzer RJ, Karam JA, Yip W, Suárez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Ürün Y, Verzoni E, Vázquez Limón JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB, LITESPARK-022 Investigators. PMID: 42384869 [PubMed - indexed for MEDLINE]
	First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA Netw Open Velasquez EL, Titus RS, Nguyen DD, Riveros C, Lalani AK, Kaushik D, Sonpavde GP, Grivas P, Wallis CJD, Satkunasivam R. PMID: 42384383 [PubMed - indexed for MEDLINE]
	The Prognostic Value of (68)Ga-PSMA and (18)F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-EB-PSMA. Ann Nucl Med Chen X, Peng Y, Zheng Q, Lai Y, Cheng H, Zhu Z, Wang G, Zang J. PMID: 42384311 [PubMed - as supplied by publisher]
	A diagnostic pitfall in suspected giant cell arteritis: metastatic renal cell carcinoma mimicking the temporal artery halo sign on ultrasound. Rheumatol Int Yamancan G, Karata. PMID: 42384226 [PubMed - in process]
	Diagnostic performance of PI-RADS and PSA density for detecting clinically significant prostate cancer. Arch Ital Urol Androl Shanaa W, Alnadhari I, Ali O, Abdeljaleel O, Abukhadijah HJ, Shamsodini A. PMID: 42383731 [PubMed - indexed for MEDLINE]
	The relationship of prostate cancer diagnosed by magnetic resonance imaging/transrectal ultrasound prostate fusion biopsy with standard and adjusted anogenital distances. Arch Ital Urol Androl Sinan Erdal F, Erbin A, Sekkeli S, Dizdaroglu C, Turkay R. PMID: 42383730 [PubMed - indexed for MEDLINE]
	Atypical urothelial cells investigation with automated urinalysis and expert review of microscopic sediment as early parameter for suspected bladder cancer patients. Arch Ital Urol Androl Noviardi DEPP, Seputra KP, Daryanto B, Dhani FK, Susianti H, Anita KW. PMID: 42383729 [PubMed - indexed for MEDLINE]
	Cost efficiency of ERAS protocols versus conventional method in urologic oncology: a systematic review of economic evaluations. Arch Ital Urol Androl Yanda A, Ismy J, Mauny MP, Khalilullah SA, Hidayatullah F. PMID: 42383727 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 179664

Page 1 of 8984



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy